Pharma clinics le medicament du mois. L'esomeprazole

[en] Esomeprazole is the last PPI registered on the Belgian market. It is the stable s-isomer of omeprazole. It has a better pharmacokinetic profile than omeprazole (racemate), allowing also better clinical performances. Esomeprazole is the first PPI shown superior to omeprazole in acute and chronic treatment of gastro-esophageal reflux disease. Controlled trials with this drug have also allowed to define new cost-effective strategies, such as on demand treatment for endoscopy-negative gastro-esophageal reflux and one week treatment of Helicobacter pylori positive duodenal ulcer.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Language :

French

Title :

Pharma clinics le medicament du mois. L'esomeprazole

Alternative titles :

[en] Pharma Clinics Medication of the Month. Esomeprazole

Publication date :

September 2002

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

610-2

Peer reviewed :

Peer reviewed

Available on ORBi :

since 05 October 2009

Statistics

Number of views

171 (2 by ULiège)

Number of downloads

182 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Louis E, DeLooze D, Deprez P, et al. - Heartburn in Belgium: prevalence, impact on daily life, and utilization of medical resources. Eur J Gastoenterol Hepatol, 2002, 14, 279-284.
Revicki D, Wood M, Maton P, Sorensn S. - The impact of gastro-esophageal reflux disease on health-related quality of life. Am J Med, 1998, 104, 252-258.
Lagergren J, Bergstrom L, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med, 1999, 340, 825-831.
Van Kemseke C, Belaiche J. - Recommandations dans la prise en charge de l'Helicobacter pylori: point de vue recent de la Société Nationale Française de Gastroentérologie. Rev Med Liège, 2000, 55, 345-349.
Louis E. - Pharma-Clinics. Le médicament du mois. Le rabéprazole (Pariet®). Rev Med Liège, 2002, 57, 53-56.
Tonini M, Vigneri S, Savarino V, Scarpignato C. - Clinicla pharmacology and safety profile of esomeprazole, the first enantiomerically pure proton pump inhibitor. Digest Liver Dis, 2001, 33, 600-606.
Lind T, Rydberg L, Kylebäck A, et al. - Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of gastro-oesphageal reflux disease. Aliment Pharmacol Ther, 2000, 14, 861-867
Röhss K, Claar-Nilsson C, Rydholm H, Nyman L. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg. Gastroenterology, 2000, 118, A20.
Wilder-Smith C, Röhss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acide control than pantoprazole 40 mg. Gastroenterology, 2000, 118, A22.
Wilder-Smith C, Röhss K, Claar-Nilsson C, Rydholm H. - Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg. Gut, 2000, 47, A63.
Andersson T, Hassan-Alin M, Hasselgren G, et al. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet, 2001, 40, 411-426.
Kharilas PJ, Falk GW, Johnson DA, et al. - Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther, 2000, 14, 1249-1258.
Johnson DA, Benjamin SB, Vakil NB, et al. - Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol, 2001, 96, 27-34.
Edwards SJ, Lind T, Lundell L. - Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther, 2001, 15, 1729-1736.
Castell DO, Kahrilas PJ, Richter JE, et al. - Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol, 2002, 97, 575-583.
Lauritsen K, Junghard O. - Esomeprazole 20 mg compared with lansoprazole 15 mg for maintenance therapy in patients with healed reflux oesophagitis. J Gastroenterol Hepatol, 2002, 17 (suppl 5), A 1007.
Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. -Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of "on-demand" therapy for 6 months. Aliment Pharmacol Ther, 2001, 15, 347-354.
Tulassay Z, Kryszewski A, Dite Petr, et al. - One week of treatment with esomeprazole-based triple therapy eradicates Helicobacter pylori and heals patients with duodenal ulcer disease. Eur J Gastroenterol Hepatol, 2001, 13, 1457-1465.
Maton PL, Vakil NB, Levine JG, et al. - Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis. Drug Safety, 2001, 24, 625-635.
Andersson T, Hassan-Alin M, Hasselgren G, Röhss K. - Drug interaction studies with esomeprazole, the (s)-isomer of omeprazole. Clin Pharmacokinet, 2001, 40, 523-537.